Table 3 Counts of bone marrow PD-1+ and TIM-3+ T cell subsets in multiple myeloma patients.

From: Quantitative and functional characteristics of circulating and bone marrow PD-1- and TIM-3-positive T cells in treated multiple myeloma patients

Cell subset

Patients in CR/PR (n = 30)

Patients with progressive disease (n = 10)

PU

CD4+PD-1+, %

5.3 (3.7–9.0)

7.1 (2.7–8.7)

0.75

CD4+TIM-3+, %

2.2 (1.2–3.2)

1.8 (1.6–3.0)

0.79

CD8+PD-1+, %

4.9 (3.3–7.1)

6.4 (6.2–11.4)

0.076

CD8+TIM-3+, %

3.5 (2.5–4.4)

5.7 (4.7–6.5)

0.033

CD4+PD-1+TIM-3+, %

0.5 (0.4–0.8)

1.5 (1.1–2.5)

0.0052

CD8+PD-1+TIM-3+, %

0.7 (0.3–0.9)

1.3 (0.9–1.6)

0.089

  1. Relative counts are presented as the percentages of bone marrow lymphocytes.
  2. Data are presented as median (interquartile range). P values are assessed with Mann–Whitney U-test.
  3. CR complete remission; PR partial response.
Back to article page